IBI3028 / Innovent Biologics, Pfizer - LARVOL DELTA

Preclinical data of IBI3028, the first clinical-stage bispecific dual-payload ADC, targeting EGFR/c-MET–positive advanced solid tumors. (ASCO 2026) - "IBI3028 demonstrated superior efficacy to AZD9592 in xenograft models with varying EGFR/c-Met expression levels. IBI3028 demonstrates outstanding preclinical efficacy and safety profile, and is well positioned as a promising broad-spectrum therapeutic for advanced solid tumors with EGFR/c-MET expression or EGFR/c-Met-driven pathogenesis."

ADC • Bispecific • Metastases • Preclinical • Oncology • Solid Tumor • EGFR • MET

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=493 | Recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

New P1 trial • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck